Drug Trial Radar · NCT07883421
Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Mar 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Tan Tock Seng HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- A*STAR Infectious Diseases Labs; World Health Organization Collaborating Centre for Reference and Research on Influenza (WHOCCRRI)
- First posted
- Oct 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the high-dose influenza vaccine can improve year-round protection in older adults aged 60 years and above. The main question it aims to answer is: • Can the high-dose influenza vaccine induce higher antibody titres at Day 14 post-vaccination compared to standard-dose influenza vaccine? Participants will: * Receive one dose of either the high-dose or standard-dose influenza vaccine * Be followed for one year, with four scheduled visits * Keep a diary of their symptoms for 3 days after vaccination * Report symptoms whenever they experience an acute respiratory infection (ARI), self-perform lateral flow assay (LFA) testing capable of detecting influenza A and B, and send nasal swabs for central testing
Conditions
- Influenza
Interventions
High-dose influenza vaccineBiological
Each dose contains 60 mcg haemagglutinin of each of the 3 influenza vaccine strains.
Standard-dose influenza vaccineBiological
Each dose contains 15 mcg haemagglutinin of each of the 3 influenza vaccine strains.
Primary outcomes
What the sponsor says the trial is designed to measure.
- GMT ratio (HD-IIV/SD-IIV) for A/H3N2 strain in the vaccineTime frame: Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Centre for Infectious Diseases (NCID)
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.